Improved prediction of response to antiretroviral combination therapy using the genetic barrier to drug resistance

Antiviral Therapy

Volumn 12, Issue 2, 2007, Pages 169-178

  Altmann, André ^a   Beerenwinkel, Niko ^b,c   Sing, Tobias ^a   Savenkov, Igor ^a   Däumer, Martin ^d   Kaiser, Rolf ^d   Rhee, Soo Yon ^e   Fessel, W Jeffrey ^f   Shafer, Robert W ^e   Lengauer, Thomas ^a  

^a MAX PLANCK INSTITUTE FOR INFORMATICS   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARVARD UNIVERSITY   (United States)

^d UNIVERSITY OF COLOGNE   (Germany)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; COMPUTER MODEL; GENETIC ANALYSIS; HUMAN IMMUNODEFICIENCY VIRUS; PHENOTYPE; PRIORITY JOURNAL; ROC CURVE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AREA UNDER CURVE; CALIFORNIA; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MODELS, STATISTICAL; PHENOTYPE; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE INHIBITORS; ROC CURVE; SOFTWARE; TREATMENT OUTCOME;

EID: 34147145974     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Reeves JD, Piefer AJ. Emerging drug targets for antiretroviral therapy. Drugs 2005; 65:1747-1766.
2. Grabar S, Le Moing V, Goujard C, Leport C, Kazatchkine MD, Costagliola D, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000; 133:401-410.
3. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med 2004; 350:1023-1035.
4. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. Panel on Clinical Practices for Treatment of HIV Infection, Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Ann Intern Med 2002; 137:381-433.
5. Jiang H, Deeks SG, Kuritzkes DR, Lallemant M, Katzenstein D, Albrecht M, et al. Assessing resistance costs of antiretroviral therapies via measures of future drug options. J Infect Dis 2003; 188:1001-1008.
6. Wang D, Larder BA, Revell A, Harrigan R, Montaner J. A neural network model using clinical cohort data accurately predicts virological response and identifies regimens with increased probability of success in treatment failures. Antiv Ther 2003; 8:U99-U99.
7. Prosperi M, Di Giambenedetto S, Trotta MP, Cingolani A, Ruiz L, Baxter JD, et al. A fuzzy relational system trained by genetic algorithms and HIV-1 resistance genotypes/virological response data from prospective studies usefully predicts treatment outcomes. Antiv Ther 2004; 9:U89-U89.
8. Prosperi M, Zazzi M, Perno CF, Di Giambenedetto S, Baxter J, Ruiz L, et al. 'Common law' applied to treatment decisions for drug resistant HIV. Antiv Ther 2005; 10:S62-S62.
9. Lathrop RH, Pazzani MJ. Combinatorial optimization in rapidly mutating drug-resistant viruses. J Comb Optim 1999; 3:301-320.
10. Beerenwinkel N, Daumer M, Oette M, Korn K, Hoffmann D, Kaiser R, et al. Geno2pheno: Estimating phenotypic drug resistance from HIV-1 genotypes. Nucleic Acids Res 2003; 31:3850-3855.
11. Beerenwinkel N, Lengauer T, Daumer M, Kaiser R, Walter H, Korn K, et al. Methods for optimizing antiviral combination therapies. Bioinformatics 2003; 19 Suppl 1:i16-25.
12. Beerenwinkel N, Daumer M, Sing T, Rahnenfuhrer J, Lengauer T, Selbig J, et al. Estimating HIV evolutionary pathways and the genetic barrier to drug resistance. J Infect Dis 2005; 191:1953-1960.
13. Rahnenfuhrer J, Beerenwinkel N, Schulz WA, Hartmann C, von Deimling A, Wullich B, et al. Estimating cancer survival and clinical outcome based on genetic tumor progression scores. Bioinformatics 2005; 21:2438-2446.
14. Larder BA, Wang D, Revell A, Lane C. Neural network model identified potentially effective drug combinations for patients failing salvage therapy. 2nd IAS Conference on HIV Pathogenesis and Treatment 13-17 July 2003, Paris, France. Poster LB39.
15. Walter H, Schmidt B, Korn K, Vandamme AM, Harrer T, Uberla K. Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors. J Clin Virol 1999; 13:71-80.
16. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: Fall 2005. Top HIV Med 2005; 13:125-131.
17. Beerenwinkel N, Rahnenfuhrer J, Kaiser R, Hoffmann D, Selbig J, Lengauer T. Mtreemix: a software package for learning and using mixture models of mutagenetic trees. Bioinformatics 2005; 21:2106-2107.
18. Beerenwinkel N, Rahnenfuhrer J, Daumer M, Hoffmann D, Kaiser R, Selbig J, et al. Learning multiple evolutionary pathways from cross-sectional data. J Comput Biol 2005; 12:584-598.
19. Hastie T, Tibshirani R, Friedman J. The Elements of Statistical Learning, 2001; pp.79-114. New York: Springer.
20. Landwehr N, Hall M, Frank E. Logistic model trees. Mach Learn 2005; 59:161-205.
21. Brun-Vezinet F, Costagliola D, Khaled MA, Calvez V, Clavel F, Clotet B, et al. Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther 2004; 9:465-478.
22. Sing T, Sander O, Beerenwinkel N, Lengauer T. ROCR: visualizing classifier performance in R. Bioinformatics 2005; 21:3940-3941.
23. Savenkov I, Beerenwinkel N, Sing T, Däumer M, Kaiser R, Lengauer T. HAART outcome prediction using statistical learning methods. Antiv Ther, 2005; 10:S60 (Abstract #55).
24. Beerenwinkel N. The evolutionary potential of HIV predicts response to antiretroviral therapy. Workshop on Quantitative Methods for Research on Antiviral Resistance. 11-12 May, 2006, Boston, MA, USA.